NCIC CTG MA.22 phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer on 2-weekly or 3-weekly schedules

ABSTRACT: This phase I/II neoadjuvant trial determined maximally-tolerated doses (MTD), dose-limiting toxicities (DLT), response-to-therapy, and explored the role of new response biomarkers. The combination regimens were delivered with acceptable toxicity, good clinical response, inducing changes in tumor RNA content and integrity. Pre-treatment gene expressions impacted clinical response, including several near 17q12, which with ERBB2, may better identify chemoresponsiveness. The NCIC Clinical Trials Group MA.22 phase I/II clinical trial (ClinicalTrials.gov identifier NCT00066443) sought to determine the optimal dosing regimens for docetaxel/epirubicin combination chemotherapy in women with locally advanced (over 95% of patients) or inflammatory breast cancer. The protocol was approved by Health C

ORGANISM(S): Homo sapiens

SUBMITTER: Baoqing Guo 

PROVIDER: E-GEOD-66999 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress